221 related articles for article (PubMed ID: 29780587)
1. Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation.
Lewis SJ; Mueller BA
SAGE Open Med; 2018; 6():2050312118773257. PubMed ID: 29780587
[TBL] [Abstract][Full Text] [Related]
2. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA
J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
Lewis SJ; Mueller BA
J Clin Pharmacol; 2021 Feb; 61(2):211-223. PubMed ID: 32851685
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy.
Economou CJP; Kielstein JT; Czock D; Xie J; Field J; Richards B; Tallott M; Visser A; Koenig C; Hafer C; Schmidt JJ; Lipman J; Roberts JA
Int J Antimicrob Agents; 2018 Aug; 52(2):151-157. PubMed ID: 29526606
[TBL] [Abstract][Full Text] [Related]
5. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.
Gharibian KN; Mueller BA
Clin Nephrol; 2016 Jul; 86(7):43-50. PubMed ID: 27251341
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation.
Lewis SJ; Jang SM; Mueller BA
BMC Nephrol; 2023 Sep; 24(1):270. PubMed ID: 37710245
[TBL] [Abstract][Full Text] [Related]
7. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
Lewis SJ; Kays MB; Mueller BA
J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
[TBL] [Abstract][Full Text] [Related]
8. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.
van de Vijsel LM; Walker SA; Walker SE; Yamashita S; Simor A; Hladunewich M
Can J Hosp Pharm; 2010 May; 63(3):196-206. PubMed ID: 22478979
[TBL] [Abstract][Full Text] [Related]
9. Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: A Monte Carlo simulation study.
Charoensareerat T; Chaijamorn W; Boonpeng A; Srisawat N; Pummangura C; Pattharachayakul S
J Crit Care; 2019 Dec; 54():77-82. PubMed ID: 31394493
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Kanji S; Roberts JA; Xie J; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
Clin Pharmacokinet; 2020 Mar; 59(3):327-334. PubMed ID: 31471789
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update.
Hoff BM; Maker JH; Dager WE; Heintz BH
Ann Pharmacother; 2020 Jan; 54(1):43-55. PubMed ID: 31342772
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of Vancomycin in Critically Ill Patients Undergoing Sustained Low-Efficiency Dialysis.
Rider TR; Silinskie KM; Hite MS; Bress J
Pharmacotherapy; 2020 Oct; 40(10):1036-1041. PubMed ID: 32866291
[TBL] [Abstract][Full Text] [Related]
13. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy.
Wang C; Chen J; Yang B; Li S; Zhang Y; Chen L; Wang T; Dong Y
Pharmacotherapy; 2023 Mar; 43(3):180-188. PubMed ID: 36714991
[TBL] [Abstract][Full Text] [Related]
14. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.
Chaijamorn W; Charoensareerat T; Srisawat N; Pattharachayakul S; Boonpeng A
J Intensive Care; 2018; 6():61. PubMed ID: 30221005
[TBL] [Abstract][Full Text] [Related]
15. Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy.
Rungkitwattanakul D; Chaijamorn W; Charoensareerat T; Charntrakarn P; Khamkampud O; Rattanaponpasert N; Srisawat N; Pattharachayakul S
J Crit Care; 2021 Jun; 63():154-160. PubMed ID: 33012583
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and individualized dosing of vancomycin for critically ill patients receiving continuous renal replacement therapy: the role of residual diuresis.
Yu Z; Liu J; Yu H; Zhou L; Zhu J; Liang G; Yang Y; Zheng Y; Han Y; Xu J; Han G; Yu L; Zhao Y
Front Pharmacol; 2023; 14():1298397. PubMed ID: 38223197
[No Abstract] [Full Text] [Related]
17. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal JA; Udy AA; Lipman J; Roberts JA
Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
[TBL] [Abstract][Full Text] [Related]
19. Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF).
Kirwan M; Munshi R; O'Keeffe H; Judge C; Coyle M; Deasy E; Kelly YP; Lavin PJ; Donnelly M; D'Arcy DM
Crit Care; 2021 Dec; 25(1):443. PubMed ID: 34930430
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis.
Crew P; Heintz SJ; Heintz BH
Am J Health Syst Pharm; 2015 Nov; 72(21):1856-64. PubMed ID: 26490819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
